Overcoming therapeutic resistance in pancreatic cancer: Emerging opportunities by targeting BRCAs and p53
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · 2023
DOI: 10.1016/j.bbcan.2023.188914 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2023. Verfasst von Juliana Calheiros und 2 weiteren Autor:innen. Beteiligte Einrichtung: LAQV/REQUIMTE, Laboratόrio de Microbiologia, Departamento de Ciências Biolόgicas, Faculdade de Farmácia, Universidade do Porto, 4050-313 Porto, Portu…. Hauptthemen laut MEDLINE: BRCA1 Protein, Pancreatic Neoplasms. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 189 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministério da Ciência, Tecnologia e Ensino Superior, Fondazione AIRC per la ricerca sul cancro ETS, Rede de Química e Tecnologia.
Abstract (Originalsprache)
Pancreatic cancer (PC) is characterized by (epi)genetic and microenvironmental alterations that negatively impact the treatment outcomes. New targeted therapies have been pursued to counteract the therapeutic resistance in PC. Aiming to seek for new therapeutic options for PC, several attempts have been undertaken to exploit BRCA1/2 and TP53 deficiencies as promising actionable targets. The elucidation of the pathogenesis of PC highlighted the high prevalence of p53 mutations and their connection with the aggressiveness and therapeutic resistance of PC. Additionally, PC is associated with dysfunctions in several DNA repair-related genes, including BRCA1/2, which sensitize tumours to DNA-damaging agents. In this context, poly(ADP-ribose) polymerase (PARP) inhibitors (PARPi) were approved for mutant BRCA1/2 PC patients. However, acquired drug resistance has become a major drawback of PARPi. This review emphasizes the importance of targeting defective BRCAs and p53 pathways for advancing personalized PC therapy, with particular focus on how this approach may provide an opportunity to tackle PC resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- LAQV/REQUIMTE, Laboratόrio de Microbiologia, Departamento de Ciências Biolόgicas, Faculdade de Farmácia, Universidade do Porto, 4050-313 Porto, Portugal.
- Department of Engineering for Innovation Medicine (DIMI), University and Hospital Trust of Verona, Verona, Italy; ARC-Net Research Centre, University and Hospital Trust of Verona, Verona, Italy.
- LAQV/REQUIMTE, Laboratόrio de Microbiologia, Departamento de Ciências Biolόgicas, Faculdade de Farmácia, Universidade do Porto, 4050-313 Porto, Portugal. Electronic address: lucilia.saraiva@ff.up.pt.
Förderung
- Ministério da Ciência, Tecnologia e Ensino Superior
- Fondazione AIRC per la ricerca sul cancro ETS
- Rede de Química e Tecnologia
- Fundação para a Ciência e a Tecnologia
- Laboratório Associado para a Química Verde
- Associazione Italiana per la Ricerca sul Cancro
Zitieren
APA
Calheiros, J., Corbo, V., & Saraiva, L. (2023). Overcoming therapeutic resistance in pancreatic cancer: Emerging opportunities by targeting BRCAs and p53. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. https://doi.org/10.1016/j.bbcan.2023.188914
Vancouver
Calheiros J, Corbo V, Saraiva L. Overcoming therapeutic resistance in pancreatic cancer: Emerging opportunities by targeting BRCAs and p53. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2023. doi:10.1016/j.bbcan.2023.188914
BibTeX
@article{Calheiros2023,
author = {Calheiros, Juliana and Corbo, Vincenzo and Saraiva, Lucília},
title = {Overcoming therapeutic resistance in pancreatic cancer: Emerging opportunities by targeting BRCAs and p53},
journal = {Biochimica et Biophysica Acta (BBA) - Reviews on Cancer},
year = {2023},
doi = {10.1016/j.bbcan.2023.188914}
}
EUVIMED